Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jacobio Pharmaceuticals has announced the successful administration of the first patient dosage in a Phase III clinical trial of its lung cancer treatment, combining Glecirasib and SHP2 inhibitor JAB-3312, with promising preliminary results. The treatment has shown a high confirmed objective response rate and manageable safety profile, advancing Jacobio’s commitment to providing innovative healthcare solutions. However, the company cautions that the success of the drug’s development and market launch is not yet assured.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.